Cubist Systematic Strategies, LLC Eagle Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 6,152 shares of EGRX stock, worth $3,691. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,152

Previous 25,812 76.17%

Holding current value

$3,691

Previous $144,000 84.72%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.71 - $6.07 $72,938 - $119,336	-19,660 Reduced 76.17%	6,152 $22,000
Q2 2024 Aug 14, 2024	BUY	$3.34 - $5.6 $86,212 - $144,547	25,812 New	25,812 $144,000
Q4 2023 Feb 14, 2024	SELL	$4.63 - $15.21 $200,492 - $658,638	-43,303 Reduced 73.98%	15,228 $79,000
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $243,010 - $365,553	-15,977 Reduced 21.44%	58,531 $923,000
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $646,445 - $1.16 Million	36,440 Added 95.72%	74,508 $1.45 Million
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $798,937 - $1.09 Million	31,881 Added 515.29%	38,068 $1.08 Million
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $154,551 - $246,056	6,187 New	6,187 $180,000
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $124,646 - $155,128	-3,021 Reduced 23.83%	9,658 $429,000
Q1 2022 May 16, 2022	BUY	$44.58 - $52.6 $194,190 - $229,125	4,356 Added 52.34%	12,679 $627,000
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $199,637 - $247,913	-4,357 Reduced 34.36%	8,323 $424,000
Q3 2021 Nov 15, 2021	BUY	$43.79 - $55.78 $190,311 - $242,419	4,346 Added 52.15%	12,680 $707,000
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $282,605 - $341,181	-7,667 Reduced 47.92%	8,334 $357,000
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $298,408 - $377,228	7,401 Added 86.06%	16,001 $668,000
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $114,062 - $140,363	2,734 Added 46.61%	8,600 $401,000
Q3 2020 Nov 16, 2020	BUY	$37.02 - $51.28 $217,159 - $300,808	5,866 New	5,866 $249,000
Q2 2020 Aug 14, 2020	SELL	$43.24 - $55.02 $236,220 - $300,574	-5,463 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$34.37 - $60.07 $187,763 - $328,162	5,463 New	5,463 $251,000
Q4 2019 Feb 14, 2020	SELL	$54.32 - $64.31 $318,423 - $376,985	-5,862 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $149,898 - $168,843	-2,815 Reduced 32.44%	5,862 $332,000
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $9,974 - $12,508	214 Added 2.53%	8,677 $483,000
Q1 2019 May 15, 2019	SELL	$38.66 - $51.82 $581,562 - $779,528	-15,043 Reduced 64.0%	8,463 $427,000
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $863,140 - $1.59 Million	23,506 New	23,506 $947,000
Q4 2017 Feb 14, 2018	SELL	$49.6 - $60.87 $325,078 - $398,941	-6,554 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $305,547 - $395,599	6,554	6,554 $391,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Eagle Pharmaceuticals, Inc. Transaction History